BenzingaSeptember 28, 2026 at 7:17 AM NY29 Days Ago
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
